Get the Stockscreener App
5.57
6.91%
0.36
After Hours:
5.42
-0.15
-2.69%
Karyopharm Therapeutics Inc stock is traded at $5.57, with a volume of 4.21M.
It is up +6.91% in the last 24 hours and down -40.43% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
See More
Previous Close:
$5.21
Open:
$5.075
24h Volume:
4.21M
Relative Volume:
4.55
Market Cap:
$109.27M
Revenue:
$146.07M
Net Income/Loss:
$-196.04M
P/E Ratio:
-0.3351
EPS:
-16.621
Net Cash Flow:
$-75.37M
1W Performance:
-27.94%
1M Performance:
-40.43%
6M Performance:
-14.96%
1Y Performance:
+14.85%
1-Day Range:
$5.00
$5.61
1-Week Range:
$5.00
$9.04
52-Week Range:
$3.51
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
5.57 | 102.21M | 146.07M | -196.04M | -75.37M | -16.62 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Rodman & Renshaw | Buy |
| Feb-05-26 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-13-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Karyopharm: Putting The Phase 3 Trial In Context (NASDAQ:KPTI) - Seeking Alpha
Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data - TradingView
KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN
KPTI: Baird Lowers Price Target, Maintains Outperform Rating | K - GuruFocus
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $15.00 at Robert W. Baird - MarketBeat
HC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $8.00 - MarketBeat
H.C. Wainwright cuts Karyopharm stock price target on trial results By Investing.com - Investing.com Canada
HC Wainwright & Co. Lowers Price Target on Karyopharm Therapeuti - GuruFocus
Karyopharm raises $30M in private placement with RA Capital By Investing.com - Investing.com Australia
Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark - Sahm
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-03-25 - Seeking Alpha
Karyopharm myeloma drug yields mixed data in myelofibrosis trial - BioPharma Dive
Karyopharm’s myelofibrosis trial meets one of two primary goals By Investing.com - Investing.com India
KPTI Shares Fall Following Varied Results from Phase III Myelofibrosis Combination Study - Bitget
Leerink cuts Karyopharm stock price target on mixed trial data By Investing.com - Investing.com Canada
Why Is Karyopharm Therapeutics Stock Trading Lower Today?Karyopharm Therapeutics (NASDAQ:KPTI) - Benzinga
Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN
Karyopharm’s Phase 3 SENTRY Trial Shows Significant Spleen Reduction and Promising Overall Survival in Myelofibrosis with Selinexor Plus Ruxolitinib 1 - Minichart
Karyopharm phase III Sentry entry bucks rux in MF; to FDA next - BioWorld MedTech
Karyopharm, looking to jump-start Xpovio, reports mixed results in myelofibrosis - Fierce Pharma
Karyopharm research and financing developments - The Pharma Letter
Karyopharm shares rise 10% after mixed Phase 3 SENTRY trial results - MSN
KPTI Stock Faces Uncertainty Amid Financial Challenges - StocksToTrade
Karyopharm Therapeutics SENTRY Trial Hits Spleen Endpoint, Shows Early Survival Signal in Myelofibrosis - MarketBeat
RBC Capital maintains Outperform on Karyopharm stock after trial data By Investing.com - Investing.com Australia
RBC Capital maintains Outperform on Karyopharm stock after trial data - Investing.com
Karyopharm Therapeutics (KPTI) Stock Plunges 12.71% on $30M Financing Announcement - Blockonomi
Karyopharm (KPTI) Announces Positive Phase 3 Trial Results for S - GuruFocus
Karyopharm Therapeutics Inc. (KPTI) Stock: Drops 12.71% After $30M Private Placement Deal - CoinCentral
Karyopharm Shares Jump 10% Following Mixed Phase 3 Trial Outcomes on Myelofibrosis Treatment - StockInvest.us
Why Did KPTI Stock Tank 13% In Pre-Market Today? - Stocktwits
Karyopharm Therapeutics (KPTI) Secures $30M in Private Placement, Stock Soars - GuruFocus
KPTI: Selinexor plus ruxolitinib nearly doubled spleen response and improved survival in myelofibrosis - TradingView
Karyopharm Therapeutics Secures $30M Private Placement with RA Capital Management - citybiz
Karyopharm Announces Financing and Positive SENTRY Trial Results - TipRanks
Karyopharm (KPTI) Shares Surge After Positive Selinexor Trial Re - GuruFocus
Karyopharm Therapeutics Raises ~$30 Million in RA Capital Private Placement, $44 Million Warrant Upside - TradingView
SENTRY myelofibrosis data and $30M private placement reshape Karyopharm (NASDAQ: KPTI) - Stock Titan
Karyopharm posts trial win for Xpovio in myelofibrosis (KPTI) - Seeking Alpha
Karyopharm (KPTI) Announces $30M Private Placement Deal - GuruFocus
Karyopharm stock gains 10% on mixed Phase 3 trial data - Investing.com UK
Karyopharm stock gains 10% on mixed Phase 3 trial data By Investing.com - Investing.com South Africa
Karyopharm raises $30M in private placement with RA Capital - Investing.com
Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study - TradingView
Karyopharm Therapeutics announces topline results from Phase 3 SENTRY trial in myelofibrosis - Traders Union
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction - Karyopharm
Karyopharm Announces $30 Million Private Placement with RA Capital - PR Newswire
New myelofibrosis drug combo shrank spleens in half of patients - Stock Titan
How The Selinexor Story Is Reframing Karyopharm Therapeutics (KPTI) And Its Growth Expectations - Yahoo Finance
Karyopharm Therapeutics Inc.: Fundamental Analysis and Financial Ratings | | US48576U2050 - marketscreener.com
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):